Inficure Bio, which is located at Umeå Biotech Incubator, was recently granted SEK 2 million from Vinnova – money that will be used to take the company’s product development to the next level. And on top of this the company has just signed its biggest deal ever.
“We have signed an agreement with Swiss company Vifor Pharma. It is our first customer in Switzerland, and it means a lot to us because we now have more opportunities to reach other customers in the Swiss market”, says Sofia Mayans.
Inficure Bio has developed a model that makes it faster and cheaper for pharmaceutical companies to test drugs for fibrosis, and in particular the presence of scar tissue in organs. Scar tissue occurs when the organ is damaged, and a common cause of organ damage is inflammation of the tissue. Although fibrosis in itself need not be a serious health problem, it can result in organ failure if it builds up. For example, fibrosis can occur in a fatty liver, where constant inflammation can create large amounts of fibrosis.
“Fibrosis contributes to more than 40 percent of all deaths in the western world and there are no effective drugs to treat fibrosis on the market yet. With our new model we can help pharmaceutical companies develop treatments for fibrosis more quickly. The market is gigantic and this agreement with Vifor Pharma is a big step in the right direction”, says Sofia Mayans, who founded Inficure Bio together with Dan Holmberg.
Inficure Bio’s agreement with Swiss Vifor Pharma will last until the end of 2019.
Presskontakt:
Sofia Mayans, PhD, CEO
+46 (0)70-366 46 66
sofia.mayans@inficurebio.com
